VCNX חוב לטווח קצר של החברה Vaccinex Inc

Immunotherapy developer Vaccinex, Inc. (VCNX) faces risks from global instability, which hinders cross-border testing and the protection of intellectual property. This chart reflects the current market value of 0.00, linking these challenges to partnerships with clinics combating brain degeneration. Processes are accelerating through the implementation of digital robots for data processing and automated antibody screening.

This indicator measures the total volume of liabilities with a maturity of up to one year, reflecting current liquidity and default risk. Monitoring short-term liabilities allows for the identification of any accounting distortions, which is critical for Vaccinex, Inc. (VCNX), as the biotech's cash deficit when funding oncology drugs is often offset by equity issuance rather than borrowing.